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The brain is a frequent site of neoplastic growth, including both primary and metastatic
tumors. The clinical intractability of many brain tumors and their distinct biology are
implicitly linked to the unique microenvironment of the central nervous system (CNS) and
cellular interactions within. Among the most intriguing forms of cellular interactions is that
mediated by membrane-derived extracellular vesicles (EVs). Their biogenesis (vesiculation)
and uptake by recipient cells serves as a unique mechanism of intercellular trafficking of
complex biological messages including the exchange of molecules that cannot be released
through classical secretory pathways, or that are prone to extracellular degradation. Tumor
cells produce EVs containing molecular effectors of several cancer-related processes
such as growth, invasion, drug resistance, angiogenesis, and coagulopathy. Notably,
tumor-derived EVs (oncosomes) also contain oncogenic proteins, transcripts, DNA, and
microRNA (miR). Uptake of this material may change properties of the recipient cells and
impact the tumor microenvironment. Examples of transformation-related molecules found
in the cargo of tumor-derived EVs include the oncogenic epidermal growth factor receptor
(EGFRvIII), tumor suppressors (PTEN), and oncomirs (miR-520g). It is postulated that EVs
circulating in blood or cerebrospinal fluid (CSF) of brain tumor patients may be used to
decipher molecular features (mutations) of the underlying malignancy, reflect responses
to therapy, or molecular subtypes of primary brain tumors [e.g., glioma or medulloblastoma
(MB)]. It is possible that metastases to the brain may also emit EVs with clinically relevant
oncogenic signatures. Thus, EVs emerge as a novel and functionally important vehicle of
intercellular communication that can mediate multiple biological effects. In addition, they
provide a unique platform to develop molecular biomarkers in brain malignancies.
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INTRODUCTION – INTERCELLULAR COMMUNICATION
IN COMPLEX BIOLOGICAL SYSTEMS
The fascination with biological identity tends to overshadow the
inherent interconnectedness of complex biological systems. The
human brain epitomizes a biological context in which function
and dysfunction is defined by patterns of information flow, which
is reflected by the intercellular exchange of defined molecular
signals.
Cellular interactions are mostly thought of as being orga-
nized intomolecular pathways of autocrine, juxtacrine, paracrine,
or endocrine nature (depending on the intercellular distances).
According to this paradigm a target cell is subjected to iterations
of individual receptor-ligand recognition events, and their net-
works, many of which are nowwell-characterized (e.g., in the case
of hormones, neurotransmitters, growth factors, and membrane
molecules and their respective receptors) (Avraham and Yarden,
2011).
This compelling model, however, has long eclipsed some
other “non-conventional” forms of cellular communication
(Mittelbrunn and Sanchez-Madrid, 2012). Indeed, it is increas-
ingly understood that cells also produce combinatorial messages
contained in cellular and membrane fragments including entities
usually regarded as confined to insoluble, intracellular compart-
ments (cytoplasm, nucleus, transport vesicles). Such bursts of
multimolecular information may be received by other cells and
lead to a change in their functional state along with elements of
their molecular identity.
Indeed, this complex form of intercellular communication
may have an ancient ancestry. This is exemplified by the phe-
nomenon of horizontal gene transfer (HGT), which is implicated
in certain forms of speciation and organismal symbiosis (Choi
and Kim, 2007; Court et al., 2008). Intriguing remnants of
such relationships include the insertion (and expression) of the
entire genome (DNA) of the intracellular prokaryote Wolbachia
in its carrier insect cell. In this sense cell fusion, phagocytosis,
and formation of viral particles by higher organisms could be
regarded as relics of intercellular integration developed during
early evolution, a process “rediscovered” in the course of var-
ious physiological and pathological processes in higher species
(Sinkovics, 2011).
The horizontal transfer of molecules is also known to occur
between human cells, including those in the brain. This process
may be executed through several different mechanisms involving
rearrangements within specialized plasma membrane domains,
and formation of direct cell–cell contact sites. Examples of such
processes include formation of intercellular junctions, membrane
swapping (trogocytosis), cellular synapses, extension of tunneling
nanotubes or cytonemes, and other mechanisms acting mostly
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between adjacent cells (Belting and Wittrup, 2008). However,
cells also posses the capacity to exchange membrane fragments
and associated complex molecular signals over longer distances
(often systemically) subsequent to the formation and release of
organelle-like structures often referred to as extracellular vesicles
(EVs), which are the main focus of this article.
BIOGENESIS AND PROPERTIES OF EXTRACELLULAR
VESICLES
EVs shed from individual cells are molecularly complex and often
highly heterogeneous. Although there is no consensus as to the
exact mechanisms that govern EV formation and their nomen-
clature, the most common descriptions point to at least four
distinct vesiculation pathways. Thus, apoptotic cellular break-
down leads to the release of large EVs (>1000 nm in diameter)
known as apoptotic bodies (AB) that contain cytoplasmic and
membrane material, genomic DNA, and organelles. Even larger
particles (large oncosomes, 1000–10,000 nm) are generated from
plasma membrane blebs, as a by-product of the amoeboid motil-
ity exhibited by certain types of cancer cells (Di Vizio et al.,
2009). Through a similar membrane blebbing mechanism vari-
ous phagocytes, microglia, platelets, and cancer cells emit smaller
EVs referred to as microvesicles (MVs), microparticles, shed vesi-
cles, or ectosomes (usually 100–1000 nm in diameter) (Thery
et al., 2009). In this case, the stimulation with biological agonists
triggers calcium fluxes, regional loss of phospholipid asymme-
try in the plasma membrane, exposure of phosphatidylserine
(PS), followed by changes in membrane-cytoskeleton contacts,
formation of membrane curvature, and vesicle scission (Piccin
et al., 2007). In microgial cells, this process involves acidic sph-
ingomyelinase (Asmase) and activation of intracellular kinase
cascades (Bianco et al., 2009). A similarmechanism is also respon-
sible for the extracellular release of certain integral membrane
receptors such as tissue factor (TF), the main trigger of blood
coagulation expressed by phagocytes and cancer cells, including
glioma (Yu and Rak, 2004; Del Conde et al., 2005). Depending
on their source, MVs may also contain cellular lineage markers,
high levels of surface PS, integrins, cannabinoid receptor (CB1),
matrix metalloproteinases (MMPs), TF, and other membrane-
related entities defining their unique biological features along
with lipids and possibly nucleic acids (Dolo et al., 2005; Bianco
et al., 2009; Camussi et al., 2010; Lee et al., 2011a).
A relatively well-studied and distinct form of vesiculation
involves the formation of exosomes. These EVs are believed to
be generated intracellularly, as the so-called intraluminal vesicles
(ILVs). These secondary vesicular structures emerge within larger
endosomal vesicles described as multivesicular bodies (MVBs)
(Simons and Raposo, 2009; Thery et al., 2009; Mathivanan et al.,
2010). Formation of MVBs represents a step in membrane recep-
tor signaling and processing cascade, which involves receptor
internalization controlled by the endosomal sorting complex
required for transport (ESCRT). This multimolecular appara-
tus controls the intracellular trafficking of membrane receptors
between cell surfaces, endosomes and pathways of lysosomal
destruction, or recycling (Williams and Urbe, 2007). It is believed
that in some instances MVBs take an alternative path and are
instead redirected to the plasma membrane in such a way as to
allow the extracellular release of ILVs (as exosomes) (Trajkovic
et al., 2008). Exosomes are relatively small (30–100 nm), rich
in tetraspanins (CD63, CD9), Rab proteins, and other cargo
including nucleic acids (Valadi et al., 2007; Thery et al., 2009).
EXTRACELLULAR VESICLES AS VEHICLES OF
INTERCELLULAR COMMUNICATION AND
MOLECULAR EXCHANGE
Emission of EVs constitutes a natural multiplexing mechanism
whereby several molecules may be assembled, protected, and
released from cells regardless of their compatibility with the clas-
sical secretory pathways. Indeed, vesiculation represents the key
mechanism whereby proteins lacking a signal peptide (e.g., inter-
leukin 1 beta–IL1β), or located in non-secretory cellular compart-
ments (e.g., nuclear proteins) may reach the extracellular space
(Bianco et al., 2009). Consequently, various proteins and nucleic
acids are incorporated into EVs, often in concentrations higher
than those found in parental cells. While the astonishing scope of
this “packaging and shipment” process has been reviewed in the
recent literature and cataloged in specialized databases (Exocarta)
(Ratajczak et al., 2006b; Valadi et al., 2007; Thery et al., 2009;
Mathivanan et al., 2012), the related mechanisms remain elu-
sive, with only limited but intriguing insights (Bolukbasi et al.,
2012).
The functional implications of cellular vesiculation can, at least
to some extent, be inferred from the repertoire of EV-associated
bioactive molecules. While EVs may contain high concentrations
of soluble mediators (interleukins, growth factors, chemokines),
their unique role in cell–cell interaction is thought to stem
largely from their content of transmembrane, cytoplasmic and
nuclear proteins, lipids, mRNA, miRs, genomic DNA sequences
(Ratajczak et al., 2006b; Valadi et al., 2007; Mause and Weber,
2010; van der Vos et al., 2011).
EVs interact with various target cells through several mecha-
nisms (Figure 1). The fate of EVs involved in such interactions
may entail either a simple surface contact with the target cell,
e.g., via receptor-ligand bridges, or several other processes. Those
include rupture of the EV membrane leading to pericellular
release of their cargo, and a burst of paracrine activity (Taraboletti
et al., 2006). However, EVs may also reach the interior of their
target cells by fusion with their plasma membranes, or through
an endocytosis-like engulfment of the entire vesicle. In these
instances, the bioactive cargo of EVs becomes released inside the
target cell, and thereby may interact with their regulatory appara-
tus including adapter proteins and signaling circuitry (Al-Nedawi
et al., 2009b). The efficiency and consequences of these cell-EV-
cell interactions may depend on the nature of the cells involved
and on the surrounding microenvironment (hypoxia, inflamma-
tion, acidity), all of which may control the emission, cargo, and
uptake of EVs. In this regard, the brain represents a unique site
for EV-mediated interactions.
EXTRACELLULAR VESICLES IN THE BRAIN
MICROENVIRONMENT
There are several cellular sources of EVs that may enter the
interstitium, fluid spaces, and other compartments of the brain
microenvironment. For example, EVs are normally present within
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FIGURE 1 | Extracellular vesicles as mediators of intercellular
communication. Exchange of molecular information between cells
may be mediated by EVs in several ways. Thus, surface receptors of
EVs may interact directly with counter-receptors on the surface
of a target cell. The latter may also come into contact with the bioactive
inner cargo of EVs upon their pericellular rupture. EVs may also merge
with the plasma membrane of the target cell, or penetrate into its
interior via endocytosis, or other processes, to release their content of
proteins and nucleic acids into the intracellular compartments (see
text for details).
the vascular system and may readily enter the brain microcircula-
tion. In the absence of disease, those are mainly EVs (microparti-
cles) released from activated blood platelets (Key et al., 2010) or
inflammatory cells. In addition, other extracranial sources may
contribute to the EV pool in the brain vasculature, including
EVs generated by peripheral inflammatory cells, endothelium, or
distant cancer cells (Smalheiser, 2009; Lee et al., 2011a). While
certain formulations of dendritic cell exosomes have been shown
to penetrate the blood-brain barrier (BBB) (Alvarez-Erviti et al.,
2011), there is no conclusive evidence for a free and consequential
exchange of naturally occurring EVs between brain parenchyma
and peripheral tissues. This could likely take place, however,
at sites of injury, or in hyperpermeable vessels associated with
tumor growth. Circulating EVs may also freely interact with brain
endothelial cells, and thereby potentially affect their state and
function, or participate in thrombosis and other forms of vascular
pathology (Chen et al., 2011). While many of these possibilities
are poorly studied, EVs and their associated ectonucleotidases
have been implicated in cytoprotective and repair events once
BBB has been disrupted (Ceruti et al., 2011).
EVs have also been implicated in various processes involv-
ing brain parenchymal cells. For instance, neuronal stem cells
(NSCs) produce EVs containing the CD133 progenitor marker
(Marzesco et al., 2005). Exocytosis is also well-described in dif-
ferentiated neurons and may impact their communication with
non-neuronal cells (Smalheiser, 2009). Indeed, neurons contain
MVBs, the structural precursor of exosomes (von Bartheld and
Altick, 2011), and these EVs are also found in supernatants of
corresponding cell cultures (Faure et al., 2006). Similarly, normal
glial cells, such as astrocytes release EVs into their surround-
ings. In this manner glial-derived glutamate may reach and act
on its receptors associated with adjacent neurons (Bergersen and
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Gundersen, 2009). Astrocytes also shed EVs containing mito-
chondrial DNA, but the significance of this process is presently
unclear (Guescini et al., 2010). Oligodendrocytes were found to
produce exosomes (Kramer-Albers et al., 2007), a process that
relies on a specific pathway involving neutral sphingomyelinase
(Nsmase) (Trajkovic et al., 2008). These EVs are then selectively
taken up by brain microglial cells, which are postulated to pro-
vide a constitutive mechanism for exosome clearance within the
milieu of the brain (Fitzner et al., 2011). Microglial cells them-
selves emit EVs containing cytokines (Potolicchio et al., 2005), a
process recently implicated in neuroinflammation (Bianco et al.,
2009). In this regard, Verderio and colleagues described a regu-
latory pathway involving Asmase, which controls ATP stimulated
release of EVs from microglial cells. In this fashion EV-associated
IL-1β, which lacks secretory signal peptide, can be liberated from
microglia and act as stimulator of phagocytosis, which is required
for clearance of ATP emitting damaged cells (Bianco et al., 2009).
Microglial EVs also play a previously unsuspected role in neu-
ronal synaptic activity (Antonucci et al., 2012). Indeed, due to
this emerging network of EV-mediated interactions in the brain
the emission and content of various vesicles was recently pro-
posed to serve as a putative biomarker for neurological disorders
(Colombo et al., 2012). It remains to be established to what extent
EV production, trafficking, and uptake contribute to the patho-
genesis of these conditions, and whether their release also has
notable systemic consequences.
BIOLOGICAL EFFECTS OF EXTRACELLULAR VESICLES
IN CANCER
The process of cellular vesiculation is hijacked and distorted
during malignant transformation and contributes to the pheno-
type of cancer cells and their associated stroma. This has been
documented in several different disease settings, and reviewed
extensively in recent literature (Ratajczak et al., 2006b; Thery
et al., 2009; Camussi et al., 2010; Rak andGuha, 2012). The role of
EVs in cancer is often a subject of generalizations, which will likely
evolve to more disease-specific considerations as the underlying
processes become better understood. It is reasonable to predict
that EVs may differ in their type and relative role in the patho-
genesis of different cancer types and disease subtypes, also as a
function of such variables as host genetic background, in a simi-
lar manner as this applies to other effector mechanisms associated
with malignancy (e.g., angiogenesis or metastasis) (Rohan et al.,
2000; Hunter, 2006; Phillips et al., 2006). Moreover, the contribu-
tion of EV release is difficult to formally demonstrate due to the
scarcity of suitable loss-of-function models in vivo, where tumor
progression could be rigorously examined in the presence and
absence of vesiculation. Nonetheless, correlative studies provide
compelling evidence for the involvement of EV generation and
exchange in several aspects of neoplasia.
Amongst the more extensively studied aspects of vesiculation
is the involvement of EVs in cancer coagulopathy. Indeed, one of
the first description of EVs was related to procoagulant micropar-
ticles emanating from activated platelets (“platelet dust”) (Wolf,
1967). This “shedding” mechanism has since been implicated
in prothrombotic, proangiogenic, and prometastatic events in
cancer (Baj-Krzyworzeka et al., 2002; Janowska-Wieczorek et al.,
2006). Seminal studies of Dvorak and colleagues revealed exten-
sive shedding of procoagulant TF-containing microvesicles from
cancer cells (Dvorak et al., 1983). Numerous subsequent analyses
interrogated the relevance of this process in cancer biology (Yu
et al., 2005), progression (Tesselaar et al., 2007), and paraneoplas-
tic (prothrombotic) syndromes (Burnier et al., 2009; Aharon and
Brenner, 2010; Khorana, 2010; Zwicker, 2010).
Production of exosomes by cancer cells has been frequently
implicated in anticancer immunity (Wolfers et al., 2001). In this
regard, both positive and negative effects of circulating exosomes
were proposed to regulate antitumor responses (Wolfers et al.,
2001; Taylor and Gercel-Taylor, 2005; Liu et al., 2006; Valenti
et al., 2007). Among the most interesting examples is the dis-
covery of exosomes containing Fas ligand, which could effectively
destroy Fas receptor—expressing cytotoxic effector T cells before
they could reach cancer cells (Abusamra et al., 2005). There
are also indications that exosomes derived from glioblastoma
(GBM) cells may exert immunomodulatory effects on monocytes
(de Vrij et al., 2012).
EVs may harbor molecular mediators of drug resistance and
transfer them between cells. This may lead to the exchange of
pro-survival proteins (Al-Nedawi et al., 2008), molecular drug
efflux pumps (e.g., P-glycoprotein/MDR1) (Jaiswal et al., 2012)
or other cargo. A similar exchange of plasma membrane frag-
ments containing drug resistance molecules may also occur upon
cell–cell contact, through a mechanism known as trogocytosis
(Rafii et al., 2008).
Cancer-derived EVs have also been implicated in metastasis.
For example, recent experimental data suggests that exosomes
cooperate with other pathways in the formation of pre-metastatic
niches and promote hematogenous metastases at distant sites
(Jung et al., 2009; Grange et al., 2011; Peinado et al., 2011).
Similarly, the influence of exosomes has been observed in the
context of lymphatic dissemination (Hood et al., 2011) and local
invasion (Hendrix et al., 2010).
EVs may also influence disease dissemination through their
impact on the vascular system including angiogenesis. In this
regard, both host and tumor-derived EVs appear to possess
an array of proangiogenic activities attributed to several ele-
ments of their cargo. Thus, EVs emanating from platelets
(Janowska-Wieczorek et al., 2005) and endothelial progeni-
tor cells (Deregibus et al., 2007) have the ability to stimu-
late the angiogenic program in resident endothelial cells. In
another study, tetraspanin (Tspan8)-containing exosomes ema-
nating from certain experimental cancer cells were found to elicit
a systemic proangiogenic state in mice harboring the correspond-
ing tumors (Gesierich et al., 2006). It is noteworthy that EVs may
contain high concentrations of soluble angiogenicmolecules such
as IL-8, VEGF, FGF (Taraboletti et al., 2006; Skog et al., 2008)
as well as proangiogenic matrix metalloproteinases (MMP9) and
their regulators (CD147). In this manner, EVs may deliver bursts
of activity to sites of blood vessel formation, in and around the
tumor, or at distant sites (Taraboletti et al., 2006). EVs may also
carry normally insoluble angiogenesis regulators such as delta
like 4 (Dll4), the cellular ligand of Notch. Presentation of Dll4
to Notch in the EV-associated form alters the biological activ-
ity of this angiogenic pathway (Sheldon et al., 2010). Moreover,
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interaction of EVs with target cells may modulate their angio-
genic phenotype, either through EV-cell contact, or by horizontal
transfer of signalingmolecules (Ratajczak et al., 2006b; Al-Nedawi
et al., 2008; Skog et al., 2008; Al-Nedawi et al., 2009a). While the
requirement for such EV-mediated communication for the onset
and regulation of angiogenesis is not fully explored, a multitude
of angiogenic effectors are already known to be released via cel-
lular vesiculation pathways, which likely influences their activity
(e.g., by changing their spatial distribution and gradients) (Mause
andWeber, 2010).
Several additional effects of EVs in cancer are also of consider-
able interest. This includes communication and reprogramming
events that may occur through contact between cancer cells
and EVs emanating from stem cells, as originally observed by
Ratajczak and colleagues (Ratajczak et al., 2006a). Other types of
progenitor-like cells are also known to shed EVs (Milsom et al.,
2008; Collino et al., 2010), and this may include tumor initiat-
ing (cancer stem) cells (TICs) identified in several malignancies
including brain tumors (Stiles and Rowitch, 2008). It is conceiv-
able that TICs may possess the capacity to reprogram activities of
other cells via the exchange of EVs.
NEOVESICULATION AND ONCOSOMES
Vesiculation of cancer cells may take several aberrant forms
including quantitative increases in EV emission, changes in their
size, structure, and molecular composition, as well as altered bio-
logical activity. Some of these anomalies may be a function of
disease-related aberration in the EV biogenesis pathways, changes
we collectively refer to as neovesiculation.
Several mechanisms have been described that effectively dif-
ferentiate the EV emission by cancer cells from that of their
corresponding non-transformed counterparts. For instance, in
prostate cancer cells, deregulation of the Akt pathway, growth fac-
tor stimulation (EGF), and loss of the diaphanous related formin
3 (DRF3) leads to the acquisition of a cellular phenotype asso-
ciated with invasiveness, amoeboid motility, and unique form of
neovesiculation. The latter is characterized by formation of very
large membrane blebs on the cell surface, and their subsequent
scission as the aforementioned unusually large EVs (large onco-
somes). Large oncosomes exhibit biological activities consistent
with their content of signaling molecules, and their formation
may be viewed as a hallmark of increased prostate cancer aggres-
siveness linked to a loss of a putative tumor suppressor (DRF3)
(Di Vizio et al., 2009).
The term oncosomes was originally coined to reflect another
distinct feature of tumor cell-derived EVs, namely their ability
to carry cancer-specific mutant proteins and nucleic acids, the
very drivers of oncogenic transformation and hitherto regarded
as confined to cancer cells. Although oncogenic mutations are
normally thought of as propagating along vertical clonal hier-
archies, the release of their containing molecules (oncoproteins
and nucleic acids) as cargo of EVs suggests that mutant gene
products may traffic horizontally between cells. In this manner,
transforming signals could be shared amongst wider cellular pop-
ulations including indolent, normal, and unrelated (heterotypic)
cells (Al-Nedawi et al., 2008). Notably, oncogene-containing EVs
were found in the interstitium, body fluids, and circulating blood
in tumor bearing animals and cancer patients (Al-Nedawi et al.,
2008; Skog et al., 2008). Through this mechanism distant organ
sites may become exposed to transforming activities, including
cells within putative metastatic niches, stem cell reservoirs, and
regulatory cell populations within the vascular system and bone
marrow (Rak and Guha, 2012). Although several long and short
range biological effects of EVs have already been described in var-
ious cancer settings (Al-Nedawi et al., 2008; Ghosh et al., 2010;
Antonyak et al., 2011), the specific role of oncogenic molecules
in these events is still to be formally demonstrated in vivo.
Several types of EVs may contribute to the extracellular release
of oncogenic cargo from cancer cells, including large and small
oncosomes and exosome-like vesicles (Al-Nedawi et al., 2008;
Skog et al., 2008; Al-Nedawi et al., 2009a; Graner et al., 2009). In
this regard cancer cell apoptosis represents a distinct mechanism,
whereby cellular remnants (AB) may serve as unique vehicles for
vesicular trafficking of mutant DNA sequences in the pericellular
milieu (Holmgren et al., 1999).
THE TRANSFORMING CARGO OF ONCOSOMES
Oncosomes may harbor several types of cancer-related molecules
including active oncoproteins, oncogenic transcripts, transform-
ing miR species, and genomic sequences containing mutant
oncogenes. Likewise, wild type or mutant tumor suppressors
(proteins and nucleic acids), and molecules affecting genetic sta-
bility (e.g., retrotransposons) have also been identified in the
cargo of cancer-derived EVs, as reviewed in the recent literature
(Ratajczak et al., 2006b; Muralidharan-Chari et al., 2010; van der
Vos et al., 2011; Rak and Guha, 2012).
Amongst the best described examples of oncoproteins found
in the cargo of cancer-derived oncosomes are members of the
ErbB/HER family of receptor tyrosine kinases (RTKs), such as
activated (phosphorylated) EGFR and its constitutively active
mutant EGFR variant III (EGFRvIII) (Al-Nedawi et al., 2008,
2009a, 2010). Breast cancer cells have been found to shed EVs
containing HER-2 protein, another member of the EGFR family
(Koga et al., 2005). Different cancer cell lines shed EVs contain-
ing other oncoproteins includingmyr-AKT (Di Vizio et al., 2009),
LMP1 (Meckes et al., 2010), Ras (Lee and Rak, 2011, unpub-
lished observation), including mutant K-ras (Franklin et al.,
2012), BRAF/V600E (Ramachandran et al., 2011), PDGFR, beta-
catenin, c-Met, and several others (Al-Nedawi et al., 2010).
EVs may also contain tumor suppressor proteins (e.g., PTEN)
(Al-Nedawi et al., 2010) and their potential role in horizontal
modulation of themalignant phenotype is a subject of an ongoing
interest.
Oncogenic nucleic acids have also been identified in the cargo
of various EVs, including transcripts for the various aforemen-
tioned oncoproteins (Skog et al., 2008; Graner et al., 2009). As
mentioned earlier, AB may carry DNA sequences associated with
the Epstein-Bar virus-related oncogenes (EBNA1, EBER), as well
as those encoding oncogenic H-ras and Myc (Holmgren et al.,
1999; Bergsmedh et al., 2001). Cell culture medium and serum
of mice harboring human medulloblastoma (MB) xenotrans-
plants may contain EVs with encapsulated DNA correspond-
ing to the amplified oncogenic c-Myc sequences (Balaj et al.,
2011), while plasma of colorectal cancer patients was found
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to contain functional circulating DNA encoding mutant K-ras
(Garcia-Olmo et al., 2010).
Pioneering work of several investigators provided ample evi-
dence as to the presence of multiple miR species in the cargo of
EVs emanating from various cell types (Ratajczak et al., 2006b;
Valadi et al., 2007; Skog et al., 2008; Taylor and Gercel-Taylor,
2008). Much research on miR detection in samples of blood
or cerebrospinal fluid (CSF) collected from cancer patients has
focused on the simultaneous isolation of all circulating miRs
including their protein- and microparticle-associated fractions
(Chen et al., 2012). Taylor profiled miRs in both the tumor tissue
and serum-derived, tumor-specific exosomes collected from ovar-
ian cancer patients. Those miRs (miR-21, miR-141, miR-200a,
miR-200c, miR-200b, miR-203, miR-205, andmiR-214) that were
present in both the tumor and exosomes, and which had been
previously identified as overexpressed in human ovarian cancer
were then validated by qRT-PCR demonstrating a direct corre-
lation between the miR signature of the tumor and that of the
tumor-derived exosomes (Taylor and Gercel-Taylor, 2008). All
of these miRs were significantly elevated in exosomes collected
from patients diagnosed with early and late stage ovarian can-
cer compared to benign ovarian disease; however, miR-200c and
miR-214 were also specifically present in higher copy numbers in
late stage malignancies. The levels of circulating let-7a and miR-
195 are significantly elevated in plasma samples collected from
breast cancer patients compared to healthy women (Heneghan
et al., 2010). These miRs were also overexpressed in the tumor rel-
ative to normal tissue. Interestingly, both aforementioned miRs
may also act as biomarkers of therapeutic response, as post-
operative levels were comparable to blood samples collected from
healthy women. In prostate cancer patients circulating miR-141
is higher compared to healthy individuals (Mitchell et al., 2008).
Furthermore, circulating miR-141 and miR-375 (also elevated in
prostate cancer specimens compared to normal tissue) are associ-
ated with metastatic disease (Brase et al., 2011). Profiling studies
of miRs found in large oncosomes in prostate cancer revealed a
pro-invasive signature. A more comprehensive list of circulating
miRNAs that may act as diagnostic and/or prognostic biomarkers
can be found in past reviews (Kosaka et al., 2010; Cortez et al.,
2011).
At least some of these miR species, may possess oncogenic and
tumor suppressive characteristics (Garzon et al., 2010). Indeed,
we observed that MB cells engineered to express miR-520g shed
EVs containing this miR into culture media and the blood of
xenograft bearing mice (D’Asti et al., 2012). Mir-520g acts as an
oncogene in these and other neuroectodermal tumors (Li et al.,
2009). Several other putative oncomirs have also been detected in
the cargo of EVs released from human GBM cells including let7a,
miR-16-1, miR-92, and miR-21 (Skog et al., 2008).
BIOLOGICAL CONSEQUENCES OF ONCOSOME PRODUCTION
The biological significance of the EV-mediated release of
oncogenic molecules is usually inferred from their inherent
transforming activity coupled with the ability to undergo inter-
cellular trafficking. While this is an intriguing possibility, there
is no formal and conclusive in vivo evidence in support of
the absolute requirement or the rate-limiting involvement of
vesiculation in key aspects of cancer progression. Nonetheless,
proof-of-principle experiments in vitro or in mouse models sug-
gest several potential pathogenetic mechanisms and the existence
of the unexpected, intercellular dimension of oncogenic signalling
(Figure 2).
Thus, EVs containing oncogenic EGFRvIII are capable of
transferring this oncoprotein into indolent glioma cells, in which
this influence activates the canonical MAPK and AKT signaling
pathways. The biological consequences of this “ectopic signaling”
include augmentation of soft agar colony formation, production
of angiogenic factors, and changes in gene expression (Al-Nedawi
et al., 2008). Tumor cell-derived EVs can also mediate the trans-
fer of EGFR to endothelial cells inducing aberrant signaling
and autocrine activation of VEGF receptors (VEGFR2). Similar
quasi-transforming in vitro consequences are associated with the
cellular uptake of EVs containing activated AKT and LMP1 pro-
teins (Di Vizio et al., 2009; Meckes et al., 2010). Exosomes can
also mediate a transfer of oncogenic K-ras between aggressive and
indolent colorectal cancer cell lines, causing transformation-like
changes (Franklin et al., 2012).
Even more dramatic outcomes were observed when non-
tumorigenic NIH3T3 fibroblasts were exposed to EVs derived
from invasive breast cancer cells containing tissue transglutami-
nase (tTG) and fibronectin (FN). Uptake of this material in vitro
and in vivo led to overt transformation and tumorigenic conver-
sion of the NIH3T3 recipients (Antonyak et al., 2011). Similarly,
DNA sequences containing oncogenic K-ras gene were detected
in association with particles circulating in blood of colorectal
cancer patients. Again, the uptake of this material by NIH3T3
cells resulted in the onset of their tumorigenic phenotype. This
phenomenon was postulated to play a role in the remote trans-
formation of normal cells and formation of distant outgrowths,
a process termed “genometastasis” (Garcia-Olmo et al., 2010).
Many of these observations are consistent with the pioneering
work of Holmgren and colleagues who originally demonstrated
that the uptake of oncogenic DNA sequences (H-ras, c-Myc)
contained in tumor cell-derived AB (EVs) may lead to the expres-
sion of the respective oncoproteins and tumorigenic phenotype
in non-transformed recipient cells (mostly NIH3T3 fibroblasts)
(Holmgren et al., 1999; Bergsmedh et al., 2001).
While the aforementioned observations raise the spectre of
EV-mediated widespread dissemination of oncogenic material
and horizontal transformation of normal cells, the likelihood
and scope of such events requires some qualification. First, the
half-life of oncoproteins and their transcripts in recipient cells is
probably somewhat limited due to breakdown and dilution dur-
ing cell division. Second, cells differ in their ability to take up,
retain, and utilize the EV-related material. In fact, shedding of
EGFR and other oncoproteins as EV cargo may represent a mech-
anism of removal of these overabundant molecules from their
parental cancer cells, and could be reiterated in EV recipients.
Aggregation of proteins at the plasma membrane may serve as a
trigger for such protective shedding processes (Shen et al., 2011;
van der Vos et al., 2011). Third, the biological effects of the uptake
of active oncoproteins by non-transformed cells may not always
be tantamount to cellular transformation. This is because normal
cells (unlike immortalized NIH3T3 fibroblasts) retain a repertoire
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FIGURE 2 | Extracellular vesicles as putative mediators of the
intercellular propagation of oncogenic signaling.While intracellular
signaling pathways elicited by mutant oncogenes (ONC) are increasingly
well understood, oncoproteins (ONC) may also operate outside of
the confines of cancer cells due to intercellular trafficking of their
containing EVs (oncosomes). Uptake of this material by proximal
non-transformed cells and at distant organ sites may trigger downstream
oncogenic signals in these recipient cells and alter their phenotype
and behavior. Thus, intercellular trafficking of oncoproteins (and nucleic
acids) extends the range of oncogenic signaling beyond the
boundaries of cells harboring the original mutation (see
text for details).
of tumor suppressors that may activate apoptotic or senescence
programs in the presence of protracted oncogenic signaling, a
phenomenon known as “oncogenic stress response” (Serrano
et al., 1995). Even established but indolent cancer-derived cells
do not necessarily undergo overt tumorigenic conversion upon
the uptake of EGFRvIII-containing oncosomes (our unpublished
observation), and additional genetic events or molecular pre-
dispositions may be required for such a change to take place.
However, the potential that at least some cells (e.g., stem cells,
premalignant cells, or dormant cancer cells) may be susceptible to
malignant conversion via oncosome-mediated molecular transfer
cannot be excluded at this time. It is also likely that more tran-
sient phenotypic changes (increased angiogenic potential, cellular
activation, stress responses) may result from exposure of vari-
ous normal and indolent cells to circulating oncosomes in cancer
patients.
MODULATION OF CANCER CELL VESICULATION BY
MICROENVIRONMENT, STRESS, AND
DIFFERENTIATION PATHWAYS
Oncogenes and tumor suppressors do not only function as cargo,
but also as a part of the regulatory circuitry that controls cellular
vesiculation in cancer. Some recent examples to this effect include
the modulation of exosome production by p53 tumor suppressor
(Yu et al., 2006) and its target known as TSAP6 (Lespagnol et al.,
2008). On the other hand, loss of p53 expression may enhance EV-
mediated emission of TF from colorectal cancer cells. Oncogenic
Ras, EGFRvIII, constitutively activated AKT (myr-AKT) exhibit
vesiculation-inducing effects in various settings (Yu et al., 2005;
Al-Nedawi et al., 2008). These intrinsic effects epitomize the
link between various intracellular pathways and regulation of
EV production in response to external stresses and stimuli. For
instance, the aforementioned p53-regulated EV emission occurs
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prominently in cells undergoing radiation responses, i.e., when
this suppressor protein is induced and plays an important biolog-
ical role (Yu et al., 2006). Analogous alterations in EV production
could be expected in cells exposed to other forms of genotoxic
or microenvironmental stress, hypoxia, metabolic deprivation, or
contact with inflammatorymediators (Svensson et al., 2011), with
possible involvement of pathways containing proto-oncogenes
and tumor suppressors. Similarly, exposure of various cells to
high concentrations of exogenous EGFR ligands (EGF, TGFα)
often triggers robust cellular vesiculation (Di Vizio et al., 2009;
Garnier et al., 2012).
Cancer cells form clonal hierarchies in which oncogenic, dif-
ferentiation, and extracellular stimulation pathways blend to con-
trol cellular composition and behavior. This includes pathways
that define cellular stemness and trans-differentiation events,
of which epithelial-to-mesenchymal transition (EMT) repre-
sents an important example. EMT is a process whereby cancer
cells of epithelial or ectodermal origin (including neuroectoder-
mal cells) transiently acquire a mesenchymal phenotype (e.g.,
vimentin positivity), as well as more motile and tumor initiat-
ing properties (Mani et al., 2008), all of which are implicated
in aggressive and metastatic growth (Thiery et al., 2009). Several
molecular events are capable of inducing EMT, including coop-
eration between Ras and TGFb signalling pathways, activation
of the MET receptor, induction of several EMT-related tran-
scription factors (e.g., YB1, Twist, or Brachyury) (Fernando
et al., 2010), blockade of E-cadherin, and other changes
(Thiery et al., 2009).
In A431 squamous cell carcinoma cells harboring an ampli-
fied EGFR gene, stimulation with EGFR ligands (TGFα) coupled
with blockade of E-cadherin results in an EMT-like state char-
acterized by the onset of vimentin expression, and spindle mor-
phology, as well as internalization of cell surface receptors, and
a profoundly altered vesiculation profile. The latter includes the
overall increase in EV emission, increase in EV-associated TF
antigen, as well as elevated emission of exosome-like particles
(Garnier et al., 2012). These changes are associated with greater
tumor initiating capacity, as measured by increased numbers of
metastatic colonies resulting from intravenous injection of A431
cells in vivo (Milsom et al., 2008). A reflection of some of these
changes could also be found in the proteome of EVs emitted
by cells that have entered the mesenchymal state as a result of
expression of oncogenic EGFR (Garnier et al., 2012) or H-ras
(Tauro et al., 2012).
Interestingly, molecular elements of the EMT-inducing
machinery may not only modulate cellular vesiculation, but also
are often found in the EV cargo. This has been observed in the
case of YB1 (Frye et al., 2009), EGFR, andMET (Al-Nedawi et al.,
2008, 2010). Since EMT often co-segregates with the elevated
tumor initiating (stem cell) capacity of cancer cells, it is possi-
ble that the accompanying changes in vesiculationmay contribute
to this process in some way; for example, by conditioning the
niche environment, influencing the adjacent host cells (Ratajczak
et al., 2006a), modulating sites of metastasis (Hood et al., 2011),
or impacting the vasculature (Gesierich et al., 2006). Indeed,
a link between cancer stem cell vesiculation and angiogenesis
has recently been described (Grange et al., 2011). It is presently
unclear whether these processes involve intercellular transfer of
oncogenic molecules.
ONCOSOMES IN BRAIN TUMORS
As in the case of other malignancies, oncogenic proteins and
nucleic acids may be emitted from brain cancer cells as EV
cargo (Al-Nedawi et al., 2008; Skog et al., 2008; Balaj et al.,
2011). Likewise, oncogenic signaling intermediates and effec-
tor molecules may be present in EVs produced by different
types of primary and secondary brain tumors, their surrounding
parenchyma, microglia, stroma, vasculature, and blood cells. The
scope of these processes and their biological impact, however, are
far from understood and only a limited number of examples have
been published to date (Al-Nedawi et al., 2008; Skog et al., 2008;
Graner et al., 2009; Balaj et al., 2011).
Initial reports suggested that biologically active, phosphory-
lated, and oncogenic EGFRvIII protein is contained in the cargo
of small (100–400 nm) EVs produced by EGFRvIII-transformed
GBM cells, and this material is emitted into the culture media and
plasma of tumor xenograft-bearing mice (Al-Nedawi et al., 2008).
These studies documented the aforementioned EV-mediated
transfer of EGFRvIII activity to indolent U373 glioma cells and
the resulting upregulation of VEGF, BclXL, and changes in levels
of other EGFR target genes, as well as increased soft agar colony
forming capacity. Co-injections of growth arrested (Mitomycin
C-treated) EGFRvIII expressing EV donor cells with GFP-tagged
indolent EV recipient glioma cells revealed the expected inter-
cellular transfer of the EGFRvIII immunofluorescence in vivo.
However, no overt tumorigenic conversion of the indolent cells
has been recorded in these experiments [(Al-Nedawi et al., 2008,
2010) and our unpublished data]. The expression of EGFRvIII,
EGFR, PDGFR, MET, PTEN, and other GBM-related oncogenic
and tumor suppressive proteins was also noted in other models of
high grade glioma (U87, U87vIII, U87-PTEN) (Al-Nedawi et al.,
2010; Lee et al., 2011b). In addition, a recent study of the phos-
phoproteome associated with EVs shed by the U373vIII GBM
cell line harboring mutant EGFRvIII revealed a rich repertoire
of proteins that have undergone this activating post-translational
modification, including molecules with oncogenic, signaling,
and gene-regulatory potential. This list includes phosphorylated
membrane receptors (EGFR, HER2, MET), intracellular pro-
tein kinases (PKC, MEK1, Raf1), regulators of apoptosis (BAD),
transcription factors (Jun, CREB1), regulators of protein trans-
lation (eIF4E, eIF2A), histones (H2B, H3.3), and DNA bind-
ing proteins (steroid receptors) (Al-Nedawi et al., 2010). In
agreement with these findings, the recent proteomic analysis of
GBM-derived exosomes documented the presence of EGFRvIII
in samples isolated from culture supernatants and patient plasma
(Graner et al., 2009).
Recent elegant studies by Skog, Breakefield and their colleagues
brought to light the presence of oncogenic nucleic acids in EVs
derived from brain tumors (Skog et al., 2008; Balaj et al., 2011;
van der Vos et al., 2011). For example, the EGFRvIII transcript
was present in the cargo of EVs isolated from culture medium
of primary GBM cell isolates, and in plasma of GBM patients
(Skog et al., 2008) as well as in corresponding circulating platelets
that appear to take up GBM oncosomes (Nilsson et al., 2011).
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Notably, levels of the EGFRvIII mRNA signal in plasma were
reduced upon surgical tumor de-bulking, which confirmed the
tumor-related origin of this material. These investigators have
also demonstrated the functionality of the EV-associated mRNA
in driving gene expression (luciferase) upon intercellular trans-
fer. These experiments documented robust biological effects of
GBM-derived EVs especially as stimulators of cellular growth and
endothelial morphogenesis (Skog et al., 2008). Molecular profil-
ing of GBM-associated EVs unveiled a rather astonishing wealth
of molecular species, including mRNA, non-coding RNA (mul-
tiple miRs), and proteins, some of which were enriched in EVs
in comparison to parental cells (Skog et al., 2008). The mech-
anism of cargo assembly and molecular enrichment during EV
biogenesis remains unclear, but in the case of mRNA this process
may depend on a specific “zipcode-like” 25 nucleotide sequence
at the 3’UTR. This motif is thought to selectively guide certain
transcripts to the regions of EV biogenesis with the help of miR-
1289 (Bolukbasi et al., 2012). Various mRNA sequences were
detected in EVs isolated from plasma of an independent cohort
of GBM patients (Noerholm et al., 2012). With a few aforemen-
tioned exceptions, studies do not provide a conclusive picture
as to the biological activity in vivo and the oncogenic poten-
tial of EV-associated molecules found in plasma of patients with
GBM, but this remains a disturbing possibility. Moreover, brain
tumor cells produce EVs containing oncomirs. This includes the
emission of miR-520g, which is a part of the 19q13.41 amplicon
associated with a subset of supratentorial primitive neuroectoder-
mal tumors (sPNET) (Li et al., 2009). As mentioned earlier, cells
transfected with the corresponding pre-miRNA gene release EVs
containing miR-520g (D’Asti et al., 2012). The emission and bio-
logical role of other oncomirs involved in primary and secondary
brain tumors have not been studied.
EVs isolated from viable brain tumor cells have also been
recently shown to contain functional DNA sequences (exoDNA).
GBM cells emit EVs that contain retrotransposons and are capa-
ble of mediating their transfer to recipient endothelial cells.
Several MB cell lines expressing the amplified c-Myc oncogene
emit the corresponding genomic sequences as EV cargo, both
in vitro and in vivo (Balaj et al., 2011). It is not clear whether
these EVs possess Myc-related biological activity. The corre-
sponding mechanisms by which the relatively large genomic
amplicon sequences may be processed into single stranded DNA
and inserted into EVs remain to be elucidated.
Similarly, it remains relatively unexplored whether any of the
recently uncovered oncogenic mutations in adult and pediatric
brain tumors manifest themselves, and contribute to the disease
progression via the release of the related mutant proteins (or
nucleic acids), as cargo of oncosomes. In this regard, some of
the intriguing examples include IDH1 G395 mutations in high
grade glioma (Yan et al., 2009), which have recently been detected
in EV preparations from GBM culture medium and CSF (Balaj
et al., 2012). Similarly, the expression of the gene fusion product
KIAA1549/BRAF in juvenile pilocytic astrocytoma (JPA) (Jones
et al., 2009) may be detectable in a similar manner, since another
form of mutant BRAF (V600E) was found in EVs collected from
plasma of melanoma patients (Ramachandran et al., 2011). Rapid
progress in molecular characterization of adult and pediatric
GBM has recently been extended to RTKs (PDGFR,MET) (Paugh
et al., 2011), mutant forms of histoneH3.3 and chromatin remod-
eling genes (Schwartzentruber et al., 2012), as well as several other
events involving genetic and epigenetic alterations (Parsons et al.,
2008; Lavon et al., 2010). It is noteworthy that by a simple anal-
ogy to the aforementioned studies on EGFRvIII, all of these newly
discovered molecular changes may result in the emission of EVs
endowed with signatures and biological activities resulting from
their content of the respective mutant genes and gene products,
and thereby may serve as biomarkers for molecular diagnosis of
the underlying brain tumors (Al-Nedawi et al., 2009b).
The central nervous system (CNS) is also a site of non-
neuroectodermal cancers including hematopoietic malignancies
and hemangioma, as well as several secondary brain tumors with
distinct molecular underpinnings. The ability of these tumors
to elaborate and shed oncosomes still remains to be studied.
Metastatic brain tumors often originate from distant cancers such
as those of the lung, breast, skin (melanoma), and several other
sites, and are associated with high morbidity, mortality, and ther-
apeutic intractability. Virtually nothing is known about the role
of oncosomes in such secondary brain tumors, in spite of the fact
that these conditions have emerged as a growing therapeutic chal-
lenge (Steeg et al., 2011). Correlative studies resulted in detection
of tumor-related DNA containing microsatellite markers of chro-
mosome 3p alterations in plasma of patients with non-small cell
lung cancer. This finding is indicative of a systemic disease, which
often metastasizes to the brain (Lleonart et al., 1998). Also p53
sequences in plasma of ovarian cancer patients may segregate with
a higher incidence of brain metastasis (Swisher et al., 2005). In all
these cases the association between circulating DNAand the emis-
sion of tumor EVs is plausible but unproven. While GBM-derived
EVs (Noerholm et al., 2012) and modified exosomes (Alvarez-
Erviti et al., 2011) may cross (or circumvent) the blood brain
barrier, this may not necessarily apply to the ability of naturally
occurring extracranial EVs to access sites of brain metastases, and
conversely, it is unknownwhether EVs emanating frommetastatic
brain tumors can freely access systemic circulaton (Steeg et al.,
2011). Therefore, it remains to be studied whether formation of
metastatic niches in the brain is related to biological activities of
cancer or stromal-derived EVs, whether oncosomes participate in
these processes, and whether signatures of brain metastases can
be found in patient plasma.
THE POSSIBLE ROLE OF EXTRACELLULAR VESICLES AS
BIOMARKERS IN BRAIN TUMORS
Brain tumors represent a significant medical challenge due to
their anatomical location, functional impact, and biological
complexity. Primary brain tumors likely originate from differ-
ent populations of NSCs and their major types include astro-
cytoma, oligodendroglioma, meningioma, ependymoma, and
embryonal brain tumors such as MB, primitive neuroectodermal
tumors (PNET), and atypical teratoid/rhabdoid tumor (AT/RT),
each associated with different age-related incidence (Wrensch
et al., 2002; Zhu and Parada, 2002; Stiles and Rowitch, 2008).
Astrocytic brain tumors constitute the most prevalent and het-
erogenous brain tumor type in adults and are divided into
grades I–IV, according to their histopathological and clinical
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characteristics. The most aggressive grade IV tumors are referred
to as glioblastoma multiforme (GBM) and presently remain
incurable (Wen and Kesari, 2008).
The rapid development of new technologies over the past
two decades resulted in the recent explosion of profiling and
sequencing studies that have profoundly altered the land-
scape of primary brain tumors (Li et al., 2012). Perhaps
the most notable development in this regard is the sub-
classification of the traditional, clinically-based nosology into
a multitude of molecularly distinct disease subtypes, each
characterized by a distinct set of driver mutations, their related
oncogenic pathways, and signature changes in the cellular
transcriptome, proteome, miR-ome, and epigenome. This com-
plexity carries enormous therapeutic implications as each molec-
ular pathway of brain tumorigenesis and disease subtype may
potentially require a different therapeutic paradigm, contain
distinct molecular targets for therapy, and could be character-
ized by separate sets of diagnostic, prognostic, and predictive
biomarkers.
Some of the more spectacular examples of recent devel-
opments in this regard include the large scale analysis of
the mutational status of human GBM with extensive verifi-
cation of several functional gains and losses (Parsons et al.,
2008). In addition to the primary and secondary pathways of
GBM progression involving some of the aforementioned genetic
events [e.g., EGFR amplification and IDH1 mutation, respec-
tively (Ohgaki and Kleihues, 2009)], high grade glioma is now
recognized to consist of at least four major molecular sub-
types (neural, proneural, classical, and mesenchymal), which
differ in their genetic and epigenetic make-up (Verhaak et al.,
2010). Although histologically similar, these tumors also dif-
fer from pediatric GBMs, which are characterized by distinct
gene expression pattern and unique mutations, involving the
growth factor RTKs (PDGFR or MET) (Paugh et al., 2011),
mutant histones (H3.3) (Schwartzentruber et al., 2012), and
several other genetic and epigenetic abnormalities. Similarly,
in MB, several molecular subtypes have recently been discov-
ered, and their molecular drivers (Myc, Wnt, SHH) described
in some detail, along with unique genetic events that may
separate primary and metastatic tumors in the same patient
(Wu et al., 2012).
It is reasonable to predict that, as in the case of EGFRvIII
in adult GBM, many (if not all) of these driver, passenger, and
signature mutations, in high and low grade adult and pediatric
glioma, MB, ependymoma, and other tumors may be present in
the corresponding patient plasma as cargo of EVs. Should the
appropriate detection methods be developed, EV platform could
become invaluable for early diagnosis, subtype determination,
longitudinal monitoring of the disease progression, and adap-
tive following of therapeutic responses (Figure 3). These are but
a few examples that illustrate the evolving oncogenic landscape
of human brain tumors and translational opportunities that EV
emission may present in this context.
In addition to the unexpectedly complex molecular nature of
brain tumors, they also exhibit considerable intra-lesional het-
erogeneity. Recent evidence suggests that while certain (classical
subgroup) GBM lesions contain regions positive for EGFRvIII
expression, this signal may be consistently absent in adjacent
tumor tissues (Biernat et al., 2004). Experimental evidence
suggests that such oncogenic mosaic is maintained in an active
manner by paracrine interactions between cancer cell popula-
tions, a process that involves interleukin 6 and other mediators
(Inda et al., 2010). Moreover, different regions of GBM may con-
tain clones expressing different oncogenic mutations of cellular
RTKs, such as amplified EGFR or PDGFR (or their mixture)
(Snuderl et al., 2011). Temporal changes in molecular profiles of
brain tumors have also been detected. This spatiotemporal and
regional complexity may result in significant sampling errors
and diagnostic challenges, especially when coupled with limited
and highly invasive access to brain tumor tissue (through surgery
or biopsy).
In this regard, the ability of brain tumor cells to shed EVs con-
taining oncogenic, mutant, or otherwise cancer-specific molec-
ular cargo opens a new window of opportunity (Figure 3). As
we and others have suggested earlier, the access to EVs circu-
lating in blood or CSF may provide an unprecedented glimpse
into the repertoire of molecular alterations occurring in indi-
vidual cancer patients and in real time. As mentioned pre-
viously, EVs isolated from plasma of mice harboring GBM
xenografts (Al-Nedawi et al., 2008) and from GBM patients
(Skog et al., 2008) have already provided a proof of principle
in this regard (e.g., detection of EGFRvIII). Preliminary exper-
iments with mouse tumors suggest that this approach may not
only permit the analysis of mutant DNA or RNA (and their
variations), but also detection of proteins that serve as targets
for biological therapeutics (e.g., phospho-EGFR). The related
molecular responses may also be reflected in circulating EVs
(e.g., EGFR dephosphorylation) (Al-Nedawi et al., 2010). In a
few anecdotal cases of GBM, plasma EV samples were found
to be positive for the mutant EGFRvIII, while this signal was
weak or undetectable in the corresponding surgical tumor tis-
sue (Skog et al., 2008; Al-Nedawi et al., 2010). This may sug-
gest that in those rare cases the EGFRvIII expressing regions
of the tumor may have been missed during tissue collection,
but the presence of this oncogene could be captured by the
analysis of EVs.
The same principle could be extrapolated to tumor-associated
stromal cells (microglia, astrocytes, vascular, and inflammatory
cells), many of which possess the ability to vesiculate, and their
EVs may reveal their functional and molecular states. Since
molecular profiling of tumor-associated host cells (in situ) has
already translated into valuable prognostic information in breast
cancer (Finak et al., 2008), so too, at least hypothetically, could
the analysis of stromal cells and their related circulating EVs in
primary and secondary brain tumors.
While considerable technological barriers still do exist, the
analysis of EVs (“vesiculome”) in patients with brain tumors may
provide unique information as to oncogenic driver mutations,
molecular signatures, oncogenic pathways, disease subgroups,
drug-resistance-associated mutations (e.g., mutations of EGFR),
and other markers. Similarly, temporal changes in the molecular
make-up of the tumor could potentially be monitored in indi-
vidual patients, along with the magnitude of drug responses. In
addition the evidence of stem cell markers, microenvironmental
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FIGURE 3 | Extracellular vesicles as a prospective biomarker platform
in molecular diagnosis of primary and secondary brain tumors.
EVs that circulate in peripheral blood or cerebrospinal fluid (CSF) can be
readily recovered using several existing methods and various microfluidic and
nanotechnology platforms under development. It may be possible to enrich
for tumor-derived EVs (oncosomes) using tumor markers (EGFRvIII) and/or
specific immunoaffinity techniques. The cargo of oncosomes may be
dissected for individual molecules (oncoproteins), their activation,
posttranslational processing (phosphorylation) and combinations, including
for the purpose of monitoring putative drug targets and their responses to
targeted therapies. EVs may provide information as to new, or pre-existing
mutations that may occur in brain tumor cells, as well as scope and
phylogeny of driver events, for example by sequencing nucleic acids (DNA,
RNA) in the cargo. Profiling of proteins and nucleic acids may reveal
signatures of brain tumor subgroups and individual variations in gene
expression. The challenge is to develop technologies that would ensure
sensitivity, specificity, reproducibility and processing of this information for
clinical purposes.
responses (e.g., by measuring levels of hypoxia-regulators such as
HIF or CAIX) and many other parameters could conceivably be
extracted from the molecular cargo of circulating EVs (Figure 3).
If successful, these approaches could have a major impact on the
design of biomarker-driven clinical trials, drug development, and
ultimately the outcomes in brain tumors.
SUMMARY
Cellular and regional heterogeneity as well as intercellular
communication emerge as key elements in the pathogenesis of
brain tumors. In this regard, the involvement of EV-mediated
molecular trafficking represents an intriguing aspect, especially as
it relates to the horizontal transfer of molecular triggers of cellular
transformation: oncogenes, tumor suppressors, and mediators of
genetic instability (Rak and Guha, 2012). In so doing, EVs could
reprogram cellular phenotypes and recruit indolent and nor-
mal cells to participate in angiogenesis, invasion, dissemination,
and other events. It is conceivable that a limited numbers of
cancer cells that underwent the initial mutation may generate
a larger “oncogenic field” by emitting EVs harboring mutant
genes (Figure 2). It is possible, therefore, that the intercellular
trafficking of EVs may serve as a target for new anticancer
therapeutics (Al-Nedawi et al., 2009a).
While the relative contribution of EV trafficking to the biol-
ogy of different types of primary and metastatic brain tumors
remains to be thoroughly investigated, the emission of EVs con-
taining molecular signatures may offer unprecedented diagnos-
tic opportunities. Development of new technologies (including
microfluidics and nanotechnology) that would secure a non-
invasive, remote, and repeated access to biological information
encapsulated in circulating EVs has already begun (Shao et al.,
2012). Thus, a better understanding of the link between cellular
transformation and vesiculation processes may have an enabling
influence on the future progress in individualized patient care.
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